The 7th DDR Inhibitors Summit covers topics such as:
- Developing Clinically Successful Wee1 & ATR Inhibitors for Cancer Therapy
- PARP Inhibition: Next-Gen PARPi’s, PARP Resistance & the Future of PARP Inhibitors
- Identifying Reliable DDR/HR Tumor Biomarkers
- Exploring the Strategy, Execution, Development & Promise of the Emerging Targets: Polθ, WRN, CHK1, DNA-PK, USP1, PARG, ATM, PKMYT1
- Developing Predictive Pre-Clinical Models in DDR to Achieve Human-Specific Translation
- Managing Toxicity - Optimizing Patient Selection, Therapeutic Window & Treatment Regimes
- Next Steps in Combination Approaches: to Heighten Drug Effect & Overcome Resistance
- Novel Methodologies, Genetic Screening & Imaging Technologies to Revolutionize Pathway Understanding, Compound Optimization & Clinical Translation
The 7th DDR Inhibitors Summit might be held in Jan 2024.
